- Home
- RMBI vs IKT Comparison
RMBI vs IKT Comparison
Compare RMBI & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMBI
- IKT
- Stock Information
- Founded
- RMBI 1887
- IKT 2008
- Country
- RMBI United States
- IKT United States
- Employees
- RMBI N/A
- IKT N/A
- Industry
- RMBI Major Banks
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- RMBI Finance
- IKT Health Care
- Exchange
- RMBI Nasdaq
- IKT Nasdaq
- Market Cap
- RMBI 140.3M
- IKT 140.5M
- IPO Year
- RMBI 2019
- IKT 2020
- Fundamental
- Price
- RMBI $14.63
- IKT $1.60
- Analyst Decision
- RMBI
- IKT Buy
- Analyst Count
- RMBI 0
- IKT 2
- Target Price
- RMBI N/A
- IKT $8.00
- AVG Volume (30 Days)
- RMBI 16.1K
- IKT 92.8K
- Earning Date
- RMBI 10-23-2025
- IKT 11-13-2025
- Dividend Yield
- RMBI 4.18%
- IKT N/A
- EPS Growth
- RMBI 17.64
- IKT N/A
- EPS
- RMBI 0.95
- IKT N/A
- Revenue
- RMBI $43,502,862.00
- IKT N/A
- Revenue This Year
- RMBI N/A
- IKT N/A
- Revenue Next Year
- RMBI N/A
- IKT N/A
- P/E Ratio
- RMBI $15.23
- IKT N/A
- Revenue Growth
- RMBI 4.48
- IKT N/A
- 52 Week Low
- RMBI $11.37
- IKT $1.12
- 52 Week High
- RMBI $15.15
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- RMBI 50.83
- IKT 44.45
- Support Level
- RMBI $14.33
- IKT $1.50
- Resistance Level
- RMBI $14.66
- IKT $1.73
- Average True Range (ATR)
- RMBI 0.35
- IKT 0.09
- MACD
- RMBI -0.04
- IKT -0.01
- Stochastic Oscillator
- RMBI 54.19
- IKT 25.47
About RMBI Richmond Mutual Bancorporation Inc.
Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans. The company has one reportable segment which is Community Banking.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.